Please login to the form below

Not currently logged in
Email:
Password:

Santhera CEO Klaus Schollmeier joins SuppreMol

He has experience at ING BHF-Bank, BASF, Knoll and Abbott

Santhera CEO Klaus Schollmeier joins SuppreMolFormer CEO of Santhera Pharmaceuticals Klaus Schollmeier has joined Germany-based biopharma SuppreMol as CEO.

Dr Schollmeier (pictured right) had served as CEO of Santhera since its formation in 2004, and was appointed chairman in October 2011.

He has both senior scientific and business experience, previously serving as managing director healthcare-biotechnology at ING BHF-Bank; head of oncology-immunology research at BASF; and general manager for BASF's operations in Western Europe.

Prior to his time at BASF, he held senior roles at Knoll and Abbott.

In his new position at autoimmune disease specialists SuppreMol, Schollmeier succeeds Professor Peter Buckell who retires.

Dr Thomas Hecht, chairman of the company's advisory board, paid tribute to Prof Buckell for his “long-standing commitment” as he welcomed Dr Schollmeier.

He said: "The company has a very promising product candidate for the treatment of autoimmune diseases in phase II clinical development with important clinical and regulatory milestones ahead. Dr Schollmeier will bring the necessary experience to the company to advance SuppreMol's products towards a Biologics License Application.”

This product is SM101, which is being investigated for its use in the treatment of primary immune thrombocytopenia (ITP) and systemic lupus erythematosus (SLE).

5th April 2013

From: Research, Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
wethepeople

wethepeople are bringing human appeal back to brand communications. Our approach allows us to create strategies, ideas and experiences that...

Latest intelligence

Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...

Infographics